Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsFRA:CN2 93 ROA % is 22.79% as of Mar. 2026, which is 13% above its 10-year median of 20.14. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €21.47 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 96.05% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Catalyst Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was €220.5 Mil.
Catalyst Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2026 was €967.7 Mil. Therefore, Catalyst Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was 22.79%.
The historical rank and industry rank for Catalyst Pharmaceuticals's ROA % or its related term are showing as below:
FRA:CN2'
s ROA % Range Over the Past 10 Years
Min: -46.63 Med: 20.14 Max: 49.21
Current: 21.35
During the past 13 years, Catalyst Pharmaceuticals's highest ROA % was 49.21%. The lowest was -46.63%. And the median was 20.14%.
FRA:CN2's ROA % is ranked better than 96.05% of 1416
companies
in the Biotechnology industry
Industry Median: -32.985
vs FRA:CN2: 21.35
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Catalyst Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's ROA % distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Catalyst Pharmaceuticals (FRA:CN2) has a ROA % of 22.79% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Catalyst Pharmaceuticals and its competitors. This is 13% above median its historical median of 20.14. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #56 out of 1416 companies in the Biotechnology industry, placing it in the top 4%.
Is Catalyst Pharmaceuticals' ROA % too high?
Catalyst Pharmaceuticals' current ROA % of 22.79% is 13% above median its 10-year median of 20.14. Based on the distribution chart, Catalyst Pharmaceuticals ranks #56 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' ROA % compare to CRNX and NAMS?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #56 out of 1416 companies for ROA %. This places Catalyst Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current ROA % is 22.79%, which is 13% above median its own 10-year median of 20.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.47, compared to a current price of €27.30 — trading 27.2% above its estimated fair value. The current ROA % is 22.79%, which is 13% above median its 10-year median of 20.14. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current ROA % is 22.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of €27.30 is trading 27.2% above its estimated GF Value™ of €21.47.
GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:CN2:
ROA %: 22.79% (13% above median its 10-year median of 20.14)
GF Value™: €21.47 vs. price of €27.30 (27.2% above fair value)
No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score
Get the complete analysis for FRA:CN2
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CN2 has been successfully added to your 
